AnalystConsensusTarget updated the narrative for NTLA

Intellia Therapeutics' consensus price target has declined from approximately $34.08 to $32.30 per share. Analysts cite heightened safety concerns surrounding recent liver injury events and paused clinical trials as key drivers behind lower valuation estimates.

Analyst Commentary

Amid Intellia Therapeutics’ recent developments, analysts have provided a range of perspectives reflecting both optimism regarding its long-term growth and caution around emerging safety concerns. Key bullish and bearish takeaways from current analyst commentary are outlined below.

• Some analysts highlight strong interest and sizable opportunity for Intellia’s gene-editing therapies, particularly NTLA-2002, with expectations of meaningful market share growth and a positive impact on revenue projections.
• Several analysts forecast upside for shares if ongoing investigations confirm recent adverse events to be isolated. This could offer potential for valuation recovery once additional safety data is available.
• Advances in trial enrollment, especially for hereditary angioedema, are cited as evidence of attractive demand for once-and-done therapies, which could drive long-term sales and provide a competitive edge.
• Bullish analysts generally maintain positive outlooks on long-term growth, citing robust clinical progress and attractive entry points given discounted shares.

• Concerns focus on the platform’s safety profile after multiple cases of grade 4 liver injury, leading to a pause in clinical trials and rapid downward revisions in price targets.
• Uncertainty persists over the timing and root causes of adverse events, as well as the potential for regulatory scrutiny and further delays to pivotal trial timelines.
• Some analysts believe the risk/benefit profile for Intellia's leading therapy is now less favorable, leading them to move to the sidelines until greater clarity on safety emerges.
• There is heightened skepticism that safety events may dampen confidence, constrain patient uptake, and cause the market to discount Intellia’s long-term valuation relative to peers.

What's in the News

• Intellia Therapeutics has temporarily paused patient dosing and screening for its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z after a patient in the MAGNITUDE trial experienced Grade 4 liver injury, meeting the trial's protocol-defined pausing criteria (Key Developments).
• Longer-term Phase 1 study data for nexiguran ziclumeran (nex-z) in hereditary ATTR amyloidosis with polyneuropathy showed deep, durable, and consistent serum TTR reductions, with favorable stability or improvement observed in clinical and biomarker measures for most patients (Key Developments).
• Completion of enrollment was announced for the global Phase 3 HAELO study of lonvoguran ziclumeran (lonvo-z) for hereditary angioedema. Intellia is planning a biologics license application submission in the second half of 2026 and a potential U.S. launch in 2027 (Key Developments).
• Nex-z, based on CRISPR/Cas9 technology, is being investigated as a potential first one-time treatment for transthyretin amyloidosis and has received Orphan Drug and RMAT Designations from the U.S. FDA and Orphan Drug Designation in Europe (Key Developments).

Valuation Changes

• Consensus Analyst Price Target has decreased from $34.08 to $32.30 per share, reflecting a modest downward revision in projected fair value.
• Discount Rate has risen slightly from 6.78% to 6.95%, indicating increased perceived risk in future cash flows.
• Revenue Growth projections have edged down from 130.66% to 130.01%, suggesting a minor reduction in expected top-line expansion.
• Net Profit Margin estimates have improved slightly from 16.06% to 16.33%, which points to anticipated operational efficiency gains.
• Future P/E ratio has decreased from 49.79x to 47.01x, which implies a small reduction in forward-looking earnings multiples.